Patent application number | Description | Published |
20100215411 | TONER ROLLER - In a toner roller that is suitable to take up a layer with toner particles on its outer surface. The toner roller has a roller-shaped inner body, and wherein a dielectric layer is arranged at an outer surface of the inner body. A high-resistance cover layer is located on said dielectric layer. | 08-26-2010 |
20130272749 | METHOD TO OPERATE A DIGITAL PRINTER WHILE CHARGING A RECORDING MEDIUM WITH IONS, AS WELL AS ASSOCIATED DIGITAL PRINTER - In a method or system to operate a digital printer for double-side printing to a recording medium with toner particles applied with a liquid developer, the digital printer prints first and second sides of the recording medium in succession. Electrophoretic mobility of toner particles of a first toner image on the first side is reduced after application of said first toner image and before application of the second toner image on the second side of the recording medium. The electrophoretic mobility is reduced by drying the first toner image along a drying route in an airflow generated by a blower such that carrier fluid is thus removed from the first toner image. After the application of the second toner image on the second side of the recording medium, both the first and second toner images are simultaneously fixed. | 10-17-2013 |
20140212631 | PRINTING ARRANGEMENT FOR TWO-SIDED PRINTING ON A RECORDING MEDIUM AND PRINTING METHOD - A printing arrangement and printing method are disclosed for two-sided printing on a recording medium, in which intermediate fixing by superheated steam takes place after printing on the first side of the recording medium. Owing to the intermediate fixing, damage to the print image of the first side during subsequent printing on the second side is avoided without the recording medium being impaired by the intermediate fixing. | 07-31-2014 |
20140212632 | PRINTING ARRANGEMENT FOR TWO-SIDED PRINTING ON A RECORDING MEDIUM AND PRINTING METHOD - A printing arrangement and a printing method for two-sided printing on a recording medium are disclosed, in which conditioning by steam and/or liquid droplets takes place after printing on the first side of the recording medium. Because of the conditioning, damage is avoided to the print image of the first side during subsequent printing on the second side, without the recording medium being impaired by the conditioning. | 07-31-2014 |
Patent application number | Description | Published |
20090130190 | Transdermal System for the Delivery of Sufentanil and Its Analogs - Methods and systems for the transdermal delivery of sufentanil and its analogs are described, from patches having a unique pharmacodynamic profile that can be used to treat persistent pain over extended periods and acute pain episodes of limited duration. | 05-21-2009 |
20100173940 | NON-MUCOADHESIVE FILM DOSAGE FORMS - Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided. | 07-08-2010 |
20120265158 | Transdermal Patch Formulation - A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch. | 10-18-2012 |
20130211351 | Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano[3,4-b]indol]-4-amine - The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient (1r,4r)-6′-fluro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4-b]indol]-4-amine or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer. | 08-15-2013 |
20130281944 | TRANSDERMAL THERAPEUTIC SYSTEM (TTS) COMPRISING ROTIGOTINE - The present invention relates to a patch containing the active ingredient rotigotine for the transdermal delivery of the active pharmaceutical agent rotigotine, comprising a backing layer (1), a matrix layer (2) containing the active ingredient, and a removable protective sheet (4) which is intended for removal before the patch is applied to the skin, characterized in that disposed with areal coverage between the matrix layer (2) and the removable protective sheet (4) is an additional interlayer (3). | 10-24-2013 |
20140170208 | TRANSDERMAL PATCH FORMULATION - A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch. | 06-19-2014 |
20140179653 | NON-MUCOADHESIVE FILM DOSAGE FORMS - Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided. | 06-26-2014 |
20140186427 | ORODISPERSIBLE FILMS FOR THE MANUFACTURING OF INDIVIDUALISED MEDICINE OR FOR LARGE SCALE PRODUCTION - The present invention pertains to oral applicable therapeutic dosage forms, in particular to orodispersible films. The present invention especially is directed to orodispersible films comprising a base layer substantially free of therapeutically active agents and a top layer comprising the desired therapeutically active agents. The present invention also concerns suitable base layers for such orodispersible films as well as therapeutical uses thereof and methods for manufacturing them. | 07-03-2014 |
20140272099 | Method for Producing and Monitoring Oral Active Ingredient Films - Method for producing and monitoring oral active ingredient films with a base to which a solution containing at least one active ingredient is applied, the method comprising the steps: • metering and mixing the base formulation, • coating the base formulation onto a substrate, so that a strip results • if necessary, drying the base formulation strip coated on the substrate • printing a colorant solution containing at least one active ingredient onto the upper side of the base formulation strip according to the flexographic printing method, • drying the base formulation strip coated on the substrate together with the printed active ingredient solution, • penetrating the base formulation strip coated on the substrate together with the printed active ingredient solution from the upper and/or lower side by means of radiation from a radiation source, • measuring the transmission of the penetrating radiation by means of at least one reception unit on the opposite side of the base formulation strip coated on the substrate together with the printed active ingredient solution. | 09-18-2014 |
20140336253 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF RIVASTIGMINE - It has been found that phenyl carbamates, in particular Rivastigmine, can be formulated as a stable TTS by using a monolayer poly alkyl (meth)acrylates, wherein the poly alkyl (meth)acrylates are substantially free of free carboxylate groups. | 11-13-2014 |
Patent application number | Description | Published |
20090012159 | HIGH PURITY BASES OF 3,3-DIPHENYLPROPYLAMINO MONOESTERS - The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C | 01-08-2009 |
20090274761 | TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN - The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C | 11-05-2009 |
20110165247 | DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF A ROTIGOTINE BASE - The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ?m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient. | 07-07-2011 |
Patent application number | Description | Published |
20080196553 | Electrical Device, in Particular an Electrical Hand-Held Power Tool - The invention is based on an electric device, in particular an electric hand tool, having a removable power supply unit ( | 08-21-2008 |
20090286143 | BATTERY PACK - A battery pack according to the invention has a housing, at least one rechargeable battery cell, and at least one temperature sensor that is attachable in a thermally conductive fashion to the rechargeable cell. At least one clamping element is provided, which cooperates with the temperature sensor in such a way that it is possible to attach the temperature sensor to the rechargeable cell in a thermally conductive fashion. | 11-19-2009 |
20100209759 | BATTERY PACK - The invention describes a battery pack having a housing and at least one battery cell. According to the invention, also provided are elements which compensates for tolerance variations of the battery cell(s). The tolerance compensation elements include at least one spreading element which is arranged in an intermediate space between at least two battery cells and/or between one battery cell and the housing. | 08-19-2010 |
20100265661 | HEAT SINK OF AT LEAST ONE ELECTRONIC COMPONENT - The invention relates to a cooling body of at least one electrical component. According to the invention, a first cooling body section is designed as a spring and a contact surface is provided on the first cooling body section, between the cooling body and the at least one component. | 10-21-2010 |
20120155030 | MOLDED PART FOR ACCOMMODATING MULTIPLE ELECTRICAL COMPONENTS - A molded part is provided for accommodating multiple electrical components and for fastening to an electrical assembly, the molded part including at least one heat sink for cooling an electrical component to be cooled, the molded part being provided to be electrically nonconductive. | 06-21-2012 |
20120313582 | HAND TOOL HAVING AT LEAST ONE INTEGRATED BATTERY CELL - In a hand tool having at least one integrated battery cell, a pen-shaped tool housing is provided, and the battery cell is connectable to a charger for charging, which is designed to charge removable battery packs. | 12-13-2012 |
Patent application number | Description | Published |
20090148531 | RATE-CONTROLLED PARTICLES - Rate-controlled particles, comprising compounds of the formula | 06-11-2009 |
20100081715 | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt or Derivative Thereof - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof a other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically ceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 04-01-2010 |
20110015216 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-20-2011 |
20120178808 | FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 07-12-2012 |
20130072508 | SOLID PHARMACEUTICAL DOSAGE FORM - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 03-21-2013 |
20140135388 | Self-Emulsifying Active Ingredient Formulation and the Use of This Formulation - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 05-15-2014 |
20140179721 | SOLID PHARMACEUTICAL DOSAGE FORM - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 5° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 06-26-2014 |
Patent application number | Description | Published |
20090220596 | Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix - A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms. | 09-03-2009 |
20090274731 | PRODUCTION OF ENVELOPED PHARMACEUTICAL DOSAGE FORMS - A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described. | 11-05-2009 |
20090302493 | PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT - A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( | 12-10-2009 |
20090311414 | PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT - A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( | 12-17-2009 |
20100119583 | SOLID DOSAGE FORM WITH A FILM CONTAINING AN ACTIVE SUBSTANCE, AS WELL AS ITS METHOD OF PRODUCTION - The present invention relates to a solid dosage form with at least one film ( | 05-13-2010 |
20100247635 | PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME - A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake. | 09-30-2010 |
20100297223 | PHARMACEUTICAL DOSAGE FORM COMPRISING A LIQUID OR FLOWABLE CORE COMPOSITION - A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50% by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4. | 11-25-2010 |
20110123652 | SELF-EMULSIFYING ACTIVE SUBSTANCE FORMULATION AND USE OF THIS FORMULATION - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 05-26-2011 |
20110182891 | PHARMACEUTICAL DOSAGE FORM COMPRISING POLYMERIC CARRIER COMPOSITION - A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form. | 07-28-2011 |
20120022089 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-26-2012 |
20120172364 | RATE-CONTROLLED PARTICLES - Rate-controlled particles, comprising compounds of the formula | 07-05-2012 |
20120202858 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 08-09-2012 |
20120225953 | Self-Emulsifying Active Ingredient Formulation and the Use of this Formulation - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 09-06-2012 |
20130118238 | TEST SOLVENT FOR EVALUATING THE COMPATIBILITY OF BIOLOGICALLY ACTIVE SUBSTANCES AND GRAFT COPOLYMERS - A liquid mixture, comprising a) at least one compound selected from polyols, polyol ethers wherein at least one hydroxyl group is unetherified, or polyalkylene ethers wherein at least one terminal hydroxyl group is unetherified, b) 1,3-bis(caprolactam-1-yl) butane, and c) diacetoxybutane mimics the solubility properties of a graft copolymer comprising a poly(alkylene glycol) backbone and a vinyl acetate/N-vinylcaprolactam copolymer grafted onto the backbone. In a method for evaluating the compatibility of a biologically active substance with the graft copolymer i) the biologically active sub-stance is brought into contact with the liquid mixture, and ii) the phase behavior of the test system and/or the solubility of the biologically active substance in the mixture is determined. | 05-16-2013 |
20130303628 | CURCUMINOID SOLID DISPERSION FORMULATION - A curcuminoid formulation, comprising a melt-processed solid dispersion product comprising one or more curcuminoids, a nutritionally acceptable thermoplastic polymer, and a phosphatide; providing an improved oral bioavailability compared to non-formulated crystalline curcuminoid. A method for producing said formulation. A nutritional product fortified with said formulation. Said formulation for use in the treatment or prophylaxis of cancer, conditions involving an inflammatory reaction, neurological disorders, cardiovascular disease, pulmonary disease, the formation of cholesterol gallstones, and parasitic infestation. | 11-14-2013 |